Brisbane, Australia – 12 October 2022 – AcuraBio (formerly Luina Bio), a leading Australian biopharmaceutical CDMO, is at BioJapan to meet with clinical-stage biopharma companies wanting to take advantage of the Australian clinical and regulatory environment to progress their drug development.
Senior scientists Timothy Evans, Head of Science and Technology, and Anthony Jay, Head of Production, are available to discuss your CDMO requirements at Booth #D-26.
AcuraBio brings two decades of experience in innovative therapeutics for customers in the biotech, pharmaceutical, and animal health industries. The CDMO provides recombinant proteins, vaccines, and complex live biotherapeutic products to customers on the leading edge in emerging therapeutics.
This is the first industry event the company is attending since rebranded AcuraBio was acquired by biotech investor Dr. Glenn Haifer and Ampersand Capital Partners.
The rebranding of the company signifies an innovative new growth phase for AcuraBio. As part of the transaction, Dr. Haifer and Ampersand are bringing significant investment to the company, with a focus on expanding the organization to better serve customers. To fuel additional growth, AcuraBio is planning to increase production facility capacity, and is actively evaluating expansion into new service offerings and technological capabilities.
To meet with the AcuraBio team please see us at Booth #D-26 or book a meeting here.
AcuraBio Pty Ltd is one of Australia’s most experienced biopharmaceutical CDMOs, offering trusted, client-focused services to both domestic and international clients for the past 20 years. AcuraBio offers significant quality, cost, and IP assurances for biopharma companies around the world. World-class researchers and proven facilities, a streamlined regulatory framework, generous tax incentives, and government funding make Australia a prime location for biotech research. AcuraBio has the following operating licenses: TGA (Australian FDA equivalent) license for the manufacture of human therapeutic APIs from biological and synthetic sources, APVMA (veterinary equivalent of the TGA) license for manufacture of sterile immunobiological products, OGTR license to produce products from genetically modified organisms, and a DAF facility license for import and use of biologic materials. Additional information about AcuraBio is available at www.acurabio.com.
About Ampersand Capital Partners
Founded in 1988, Ampersand is a middle market private equity firm with more than $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience in seeking to build value and drive strong long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. Additional information about Ampersand is available at www.ampersandcapital.com.